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Abstract: Tight glycaemic control is now benefiting medical and surgical intensive care patients
by reducing complications associated with hyperglycaemia. Once patients leave this intensive
care environment, less acute wards do not continue to provide the same level of glycaemic
control. Main reason is that these less acute wards do not have the high levels of nursing
resources to provide the same level of glycaemic control. Therefore developments in protocols
that are less labour intensive are necessary. This study examines the use of insulin glargine
for basal supplement in recovering critically ill patients. These patients represent a group who
may benefit from such basal support therapy. In silico study results showed the potential in
reducing nursing effort with the use of glargine. However, a protocol using only glargine for
glucose control did not show to be effective in the simulated patients. This may be an indication
that a protocol using only glargine is more suitable after discharge from critical care.
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1. INTRODUCTION
Stress-induced hyperglycaemia is prevalent in critical care
and can occur in patients with no history of diabetes
(Capes et al., 2000; Van Den Berghe et al., 2001). Hy-
perglycaemia worsens outcomes, increasing the risk of se-
vere infection (Bistrian, 2001), myocardial infarction (Mc-
Cowen et al., 2000) and critical illnesses such as polyneu-
ropathy and multiple organ failure.
A number of studies have investigated the effects on
patient outcomes when blood glucose levels are controlled
with insulin, and revealed markedly positive results. The
most notable is a study by Van Den Berghe et al. (2001)
that showed tightly controlled glucose levels averaging
6.1mmol/L reduced cardiac intensive care unit (ICU)
patient mortality by 18-45%. The use of intravenous (IV)
insulin therapy in ICU patients to lower hyperglycaemia,
whether or not a patient is a diagnosed diabetic, became
the focus of much discussion following this landmark study.
Krinsley (2004) showed a 17-29% reduction in mortality
over a wider ICU population with a higher blood glucose
average of 7.75mmol/L. Finally, the SPRINT protocol
reduced mortality 36-47% with a more critically ill cohort
(Chase et al., 2008a).
SPRINT or Specialised Relative Insulin Nutrition Tables
protocol (Chase et al., 2008a) is a simple wheeled-based
system that modulates insulin and nutritional inputs for
tight glycaemic control. SPRINT uses the absolute blood
glucose level, change in blood glucose level, and current
insulin and nutrition administration rates to identify effec-
tively the patient’s insulin sensitivity and respond accord-
ingly. The unique wheel-based designed of SPRINT allows
all of these metrics to be incorporated into an essentially
nurse-automated protocol.
While many ICU patients are benefiting from tight blood
glucose control (TGC), moderate to high levels of hy-
perglycaemia are still tolerated within less acute wards.
The use and benefits of insulin protocols within these
units have not yet been widely addressed in the literature
(Whitehorn, 2007). The management of glycaemic levels
in these units remains under the influence of ineffective
standard characterized by a tolerance for hyperglycaemia
and a reluctance to use insulin intensively.
Based on current evidence from studies in medical and
surgical ICUs, it is logical to expect that the mainte-
nance of normoglycaemia within less acute ward patients
would limit potential complications associated with ele-
vated blood glucose levels. This assumption is not unrea-
sonable as patients in the ICU and less acute wards share
an accelerated catabolic, hyperglycaemic state that also
reduces the immune response. Extending tight control to
these wards could minimise rebound hyperglycaemia on
discharge to the wards (Goldberg et al., 2004) and mini-
mize the development of (new) infections, thus improving
overall patient care.
However, to fully implement TGC in less acute wards pose
a challenge as these wards do not have the same nursing
resources compared to ICU, making constant monitoring
and titration difficult. Hence, there is a pressing need
for insulin delivery protocols that can be successfully
implemented with minimal clinical effort and resources.
This study uses an integrated pharmaco-kinetics/dynamics
model of insulin glargine, intravenous insulin and glucose
from Wong et al. (2008a,b) and Lin et al. (2010) to simu-
late less intensive TGC protocols using insulin glargine for
provision of basal insulin. A retrospective cohort consisting
of 10 metabolically stable patients were selected from a
cohort of ICU patient receiving TGC with the SPRINT
protocol (Chase et al., 2008a). These patients represent
a group that may benefit from less intensive protocols
that uses insulin glargine as basal supplement. Effective
use of insulin glargine, commonly injected once or twice
a day, promises a potential to reduce nursing workload,
which has added benefits (Chase et al., 2008b). Effective
protocols indicated by positive simulation results can then
be considered for a clinical pilot study, moving one step
closer to providing TGC in the less acute wards.
2. SYSTEM MODEL
The pharmacodynamic model used in this study integrates
an insulin glargine compartmental model from Wong et al.
(2008a,b) and a generic insulin-glucose model, ICING,
from Lin et al. (2010). The glargine model has been
validated against literature results (Wong et al., 2008a,b)
and the model ICING from Lin et al. (2010) has been
clinically validated in data from critically ill patients. The
integrated model in this study is defined:




1 + kprep,gla(t)rdis,max pgla(t)
+ up,gla(t) (1)
Hexameric State:
˙xh,gla =−(k1,gla + kd)xh,gla(t)
−kprep,gla(t)pgla(t)
1 + kprep,gla(t)rdis,max pgla(t)
+ uh,gla(t) (2)
Dimeric/Monomeric State:
˙xdm =−(k2 + kdm)xdm(t) + k1,glaxh,gla(t)
+um,gla(t) (3)
Interstitium:
x˙i = k2xdm(t)− (kdi + k3)xi(t) (4)
where all the variables in Equation (1)–(4) are defined in
Table 1.
Glucose-Insulin Physiology Model
G˙=−pGG(t)− SIG(t) Q(t)1 + αGQ(t)
+
P (t) + EGPb − CNS
VG
(5)
Table 1. Nomenclature for the Insulin glargine
compartmental model
xh,gla(t) Mass in glargine hexameric compt. [mU]
pgla(t) Mass in glargine precipitate compt. [mU]
xdm(t) Mass in dimer monomer compartment [mU]
xi(t) Mass in the interstitium compt. [mU]
rdis,max Max glargine precip. dissolution rate [mU/min]
utotal,gla(t) Insulin glargine input [mU/min]
up,gla(t) Glargine precip. state insulin input [mU/min]
uh,gla(t) Glargine hexamer state insulin input [mU/min]
um,gla Glargine dimer/monomer state insulin
input
[mU/min]
kprep,gla(t) Glargine precipitate dissolution rate [min-1]
k1 Hexamer dissociation rate [min-1]
k1,gla Glargine hexamer dissociation rate [min-1]
k2 Dimeric/monomeric insulin transport
rate into interstitium
[min-1]
k3 Interstitium transport rate into plasma [min-1]
kdi Rate of loss from interstitium [min-1]
kd Rate of diffusive loss from hexameric and
dimeric/monomeric state compartments
[min-1]
Q˙= nI(I(t)−Q(t))− nC Q(t)1 + αGQ(t) (6)







P˙1 =−d1P1 +D(t) (8)
P˙2 =−min(d2P2, Pmax) + d1P1 (9)
P (t) =min(d2P2, Pmax) + PN(t) (10)
uen(t) = k1e
− I(t)k2k3 when C-peptide data are
not available (11)
where all the variables in Equations (5)–(11) are defined
in Table 2.
3. METHOD
The effectiveness of glargine for blood glucose control is
assessed in silico. Patient data were selected retrospec-
tively for the simulation study from a cohort of patients
who received insulin therapy under the SPRINT protocol
during their stay in the Christchurch Hospital ICU (Chase
et al., 2008a). SPRINT uses insulin boluses and modulates
feed rate hourly to maintain blood glucose levels within a
desirable range of 4.0–6.1 mmol/L. It takes into account
of a particular patient’s apparent insulin sensitivity at any
given time to determine the insulin bolus size and feed
rate.
The use of glargine is intended for patients who are
recovering from their critical illness, and heamo-stability
had been regained. The patients selected for simulation
are those who exhibit metabolic stability within 30 hour
of ICU admission. Metabolic stability in patients in terms
of stable blood glucose-insulin response is defined by:
• Hourly insulin boluses ≤ 3U for at least 12 hours.
• Hourly feed rate of ≥60% of individual patient’s goal
feed rate.
Table 2. Nomenclature for ICING model
G Blood glucose level [mmol/L]
Q Interstitial insulin level [mU/L]
I Plasma insulin level [mU/L]
EGP Endogenous glucose production [mmol/min]
EGPb Basal endogenous glucose production [mmol/min]
CNS Central nervous system glucose uptake [mmol/min]
pG Insulin independent glucose removal (ex-
cluding CNS) and the suppression of
EGP from EGPb with respect to G
[min−1]
SI Insulin mediated glucose removal and the
suppression of EGP from EGPb with
respect to G and Q
[L/mU/min]
αG Saturation parameter for insulin medi-
ated glucose removal
[L/mU]
VG Plasma glucose distribution volume [L]
P (t) Glucose appearance in plasma from dex-
trose intake
[mmol/min]
nI Plasma-interstitium insulin diffusion rate [min
−1]
nC receptor-bound insulin degradation [min
−1]
nK insulin clearance through kidneys [min
−1]
nL insulin clearance through liver [min
−1]
αI Saturation parameter for insulin clear-
ance through liver
[L/mU]
uex(t) Exogenous insulin [mU/min]
uen(t) Endogenous insulin [mU/min]
VI Insulin distribution volume [L]
xL First pass hepatic clearance
P1 Glucose level in stomach [mmol]
P2 Glucose level in gut [mmol]
d1 Glucose absorption rate from stomach [min−1]
d2 Glucose absorption rate from gut [min−1]
D(t) Enteral dextrose intake [mmol/min]
PN(t) Parenteral dextrose intake [mmol/min]
Pmax Maximal glucose flux from gut to plasma [mmol/min]
k1 Basal endogenous insulin production [mU/min]
k2, k3 Generic constants for exponential sup-
pression of uen with elevated I
Ten patients were chosen from the entire SPRINT cohort
(Chase et al., 2008a). Males make up 70% of the patients
selected for the in silico assessments. Median age of these
patients is 53.5 [IQR: 44,73] years old. Median APACHE II
score is 18 with IQR=[12,19]. The average length of stay
is 6.6 days (Range: 5.6–10 days). Mortality is 0 for the
selected patients.
Time-varying insulin sensitivity SI was fitted hourly to
clinical patient data using Equations (5)–(11) and an
integral fitting method (Hann et al., 2005). Constraints
are placed on SI to ensure it is within a physiologically
valid range. The resulting time-varying SI profiles repre-
sent time-varying metabolic status for individual patients.
Thus these profiles of SI can act as “virtual patients” for
testing different glycaemic control protocols. This “virtual
patient” simulation method had been shown to be an
accurate way of predicting the effect of different insulin
therapies (Chase et al., 2007; Lin et al., 2008).
Because SPRINT operates on the basis of estimating the
patient’s “apparent” insulin sensitivity (i.e. how much
glucose can be removed by the amount of insulin bolus
given), the protocol is still applicable when there is a
background insulin infusion or similarly, glargine. “Virtual
trials” are performed using SPRINT with and without
daily doses of glargine. The results from virtual trials are
compared to clinical data for the goodness of control,
amount of insulin and feed given, and nursing effort
intensity. Specifically, nursing effort intensity is measured
by the number of intervention required, which includes
measuring blood glucose levels, adjusting feed rates, giving
SPRINT IV insulin boluses, and giving glargine boluses.
The frequencies of blood glucose measurements, changes
in feed rates and IV insulin boluses are governed by the
SPRINT protocol (Chase et al., 2008a). In particular,
blood glucose levels are measured hourly unless 3 hourly
measurements have been within 4–6.1 mmol/L. In which
case, measurement frequency is changed to 2 hourly until
blood glucose levels fail to stay in the 4–6.1 mmol/L band.
Four different protocols involving the use of glargine are
tested to evaluate their potentials for a clinical pilot study.
Table 3 lists the full descriptions of simulation protocols
that are carried out in this study.
Table 3. Description of protocol simulations.
Protocol Description
Clinical records Clinical data from Chase et al. (2008a)
SPRINT Simulation of the protocol SPRINT
Chase et al. (2008a)
SPRINT+Glargine Simulation of SPRINT protocol with in-
sulin glargine as a basal insulin replace-
ment therapy
SPRINT-1U+Glargine Simulation of SPRINT protocol with in-
sulin glargine where the boluses calcu-
lated using SPRINT are reduced by 1U
SPRINT-2U+Glargine Simulation of SPRINT protocol with in-
sulin glargine where the boluses calcu-
lated using SPRINT are reduced by 2U
Glargine Only Simulation of daily glargine IV insulin
boluses from SPRINT
The dosing frequency of glargine is 24 hours, where the
first dose is given at 12 hours after ICU admission. The
size of the initial glargine bolus is the sum of SPRINT
insulin boluses administered during the previous 12 hours.
The following glargine boluses are calculated as being
half of the total daily insulin (IV boluses + glargine)
from the previous day. Each bolus is capped at 40U for
safety against hypoglycaemia, except when glargine is
simulated without the use of SPRINT. In the case where
only glargine is used for blood glucose control, a cap of 72
U/day is used. In addition, clinical records of feed rates
are used in the simulations without SPRINT.
4. RESULTS
A summary of the results for all 10 patients is shown in
Table 4. The blood glucose levels from simulation results of
SPRINT are very similar to clinical records, confirming the
validity of the virtual trial method. The range in feed for
SPRINT is much tighter than clinical records. This can be
expected as feed rate is often turned off for patients in real
life during various medical procedures. The simulation of
SPRINT however does not let the feed rate drop to below
30% of an individual’s goal feed rate.
In the simulations of SPRINT+Glargine, a lot more insulin
in total is used even though the amount of IV bolus
from SPRINT has decreased. The amount of IV insulin
bolus used in SPRINT+Glargine protocol is 15% less
than SPRINT, and 10% less than clinical records. The
control in blood glucose levels (BG) is still good, with a
median 75% [IQR: 69.5–80.4%] time in 4.0–6.1 mmol/L
Table 4. Protocol result summary. Values are shown in median [IQR].
Time in Hypoglycaemia Total IV Insulin Intervention
BG∗ 4.0–6.1 mmol/L <2.2 mmol/L Insulin Bolus Glargine Feed Frequency#
Protocol [mmol/L] band [%] [%] [U/day] [U/day] [U/day] [mmol/day] [N/day]
Clinical 5.25 [4.97, 5.59] 81.9 [76.9, 88.2] 0 57.8 [44.6,64.8] 57.8 [44.6,64.8] 0 113 [103,122] 39 [36,41]
SPRINT 5.27 [5.01, 5.62] 81.0 [70.8, 83.4] 0 61.1 [52.3,64.2] 61.1 [52.3,64.2] 0 125 [113,125] 37 [36,38]
SPRINT+Glargine 5.38 [5.06, 5.80] 75.0 [69.5, 80.4] 0 89.6 [79.4,94.8] 52.0 [42.6,55.4] 37.6 [36.8,38.4] 125 [113,136] 35 [33,36]
SPRINT-1U+Glargine 5.65 [5.35, 6.00] 72.0 [61.6, 74.4] 0 78.0 [71.3,80.3] 40.4 [35.2,41.9] 37.6 [36.1,38.4] 125 [ 89,125] 37 [36,38]
SPRINT-2U+Glargine 6.25 [5.83, 6.63] 58.3 [59.8, 79.2] 0 64.9 [62.1,66.6] 27.6 [26.4,28.8] 37.3 [35.7,37.8] 95 [ 70,105] 38 [36,39]
Glargine Only 7.34 [6.86, 7.77] 14.4 [10.3, 18.3] 0 60.0 [56.7,64.9] 0 60.0 [56.7,64.9] 112 [103,122] 19 [17,22]
∗BG = Blood Glucose
# Intervention Frequency= BG measurements + feed rate adjustments + number of insulin bolus + number of glargine bolus
glycaemic band. Feed rate is comparable to SPRINT,
however the upper quartile is significantly higher. This is
because patients are still given similar amount of insulin
towards their end of ICU stay, resulting in patients being
able to receive a lot more feed during this time. The most
noticeable difference in SPRINT+Glargine compared to
SPRINT and clinical records is the reduction in nursing
effort, expressed in intervention frequency.
When SPRINT is reduced by 1 and 2 U while glargine
is given daily, the tightness of BG is reduced as well as
the total amount of insulin used. The amount of feed is
also reduced for these two protocols. Because of the loss
in tightness of control, intervention frequency is actually
not reduced with the use of glargine in these simulations.
The percentage of time spent within desired band reduced
to only 14.4% in the simulation using Glargine only. The
daily glargine amount just meet the patient’s requirements
when comparing to the total amount of insulin used
clinically. As glargine is known to have a slow build up, and
can take 3 days or more to reach a steady plasma insulin
level (Lehmann et al., 2009), the significant decrease in
time in band is not a surprise. Finally, all protocols are
safe with respect to hypoglycaemia.
Clinical records and simulation results of SPRINT+
Glargine on patient 5122 are shown in Figure 1. The top
panel of each subfigure shows the blood glucose levels
(BG) through time. BG is well controlled with median
and IQR of 5.20 [4.90,5.60] and 5.14 [4.82,5.82] for clinical
and SPRINT+Glargine respectively. The percentages of
time spent within 4.0–6.1 mmol/L for the whole duration
of patient 5122’s stay are 83.0% for clinical and 78.3%
for SPRINT+Glargine. There is no occurrence of hypo-
glycaemia described at BG below <2.2 mmol/L at any
period. The median daily feed given in clinical records is
117 g/day against 126 g/day from the SPRINT+Glargine
protocol. The simulation results for SPRINT is very simi-
lar to clinical records in all respects.
For patient 5122 in Figure 1, the frequency and amount
of insulin bolus in clinical data are higher than simulated
SPRINT+Glargine. Clinical records showed 17% more IV
insulin than SPRINT+Glargine. The frequency of insulin
boluses given for patient 5122 is 144 boluses in clinical
records against 125 boluses for SPRINT+Glargine (equiv-
alent to 22 and 18 boluses per day). In terms of nursing
effort, clinical records showed 262 interventions in total
(40/day) whereas SPRINT+Glargine protocol showed 222
interventions (33/day). The higher intervention frequency
is mostly attributed to measuring BG. In the simula-
tions of SPRINT+Glargine, BG never dropped below 4
mmol/L whereas there was one such instance in the clinical
records, as shown in Figure 1. The avoidance of low BG
for patient 5122, probably due to less IV insulin boluses
given, contributed to most BG being measured at 2 hourly
intervals, cutting back on nursing effort. The reduction in
the number of IV boluses in SPRINT+Glargine becomes
more observable towards the second half of patient 5122’s
stay. This could be explained by the slow build up of
plasma insulin level from glargine (Lehmann et al., 2009).
5. DISCUSSION
This study evaluates the safety and efficacy of using insulin
glargine to supplement TGC for patients whose insulin
requirement for TGC is stable. These patients constitute
a group who require a stable, constant “uplift” in their
insulin production during their illnesses. The extra require-
ment may be due to temporary insulin resistance, brought
on by excess catecholamines during illness (Bistrian, 2001;
McCowen et al., 2000), or temporary impaired endogenous
insulin production.
The simulation results from SPRINT are very similar
to clinical records. Therefore the virtual patient simula-
tion method is a realistic way to assess different TGC
protocols. The simulations of SPRINT+Glargine in this
study shows glargine can be used successfully in patients
who are insulin resistant but metabolically stable. The
results showed reduced nursing effort while still deliver-
ing tight control. The blood glucose levels achieved with
SPRINT+Glargine are comparable to SPRINT and clini-
cal records. The feed rates are also comparable in the two
simulated protocols and clinical records. The amount of
insulin used in SPRINT+Glargine is greater than SPRINT
and clinical records. This could be due to the slow build
up of insulin glargine, which could take 3 days or longer
(Lehmann et al., 2009; Heise et al., 2002).
By reducing the amount of bolus in SPRINT by 1U while
still maintaining insulin glargine (SPRINT−1U+Glargine),
the results in terms of BG level are still compara-
ble to clinical records. However, the simulations of
SPRINT−2U+Glargine and Glargine Only are not suffi-
cient to provide effective glycaemic management for these
patients even though the total insulin used is comparable
to clinical data. This could be explained by the slow build
up of insulin glargine as mentioned above. The average
stay of 6.6 days may not be adequately long for the
(a) Clinical (b) SPRINT+Glargine
Fig. 1. Comparison between clinical and SPRINT+Glargine simulation results on Patient 5122. In the top panel of each
subfigure, the solid line (–) illustrates the modeled BG while crosses (×) are the clinically recorded BG. The second
panel of each subfigure shows the insulin bolus (–) and insulin glargine (· · ·). The bottom panel of each subfigure
displays the feed.
adaptation of glargine. Even though the patients selected
for this study are reasonably stable, critically ill patients
in general appear to require more rigorous insulin therapy
than using long term insulin supplement such as glargine.
This indicates a protocol using glargine only is perhaps
only suitable for the less acute wards. However, an early,
smooth transition from IV insulin to a combination may
help by reducing undesirable variations in blood glucose
levels (Egi et al., 2006).
The use of glargine is very conservative in this study,
being less than or equal to half of the daily insulin
requirement from the previous day. This is to address the
course of recovery for patients where they are expected
to slowly regain normal insulin sensitivity or basal insulin
production.
The protocol SPRINT did not seem to be sensitive to
glargine supplementing a patient’s insulin requirement.
This may be due to the design of SPRINT aiming to
achieve a steady state of 3U insulin and 60% of feed in
patients. In addition, due to the fact that SPRINT is
designed in the format of look-up tables, its adjustments
in insulin and feed are rather discretized. By reducing
SPRINT insulin by 1U while glargine is given to patients
in simulations, the control in blood glucose levels is not
compromised. This protocol, with further investigation
and revision, may have the potential of being employed
in a clinical pilot study. A clinical pilot study will pro-
vide valuable information on the practicality and clinical
benefit of glargine in stable ICU patient. This will be the
first step towards designing glycaemic control protocols
for patient in the less acute wards. After all, SPRINT has
been proven to provide safe TGC and gained considerable
trust in Christchurch Hospital ICU where it is first imple-
mented. A clinical pilot study incorporating SPRINT will
be significantly easier to deploy compared to a protocol
without it.
Finally, this study only included 10 patients, therefore
its results are only a positive “proof-of-concept”, and
not conclusive. However, the use of glargine is shown to
supplement a patient’s basal insulin requirement and has
the potential to reduce nursing effort. Further reduction
in nursing effort without compromising tight control may
be possible by revising the blood glucose measurement
frequency (3 to 4 hourly) while patients are receiving
glargine.
6. CONCLUSION
This study investigated the use of glargine as basal insulin
support in stable, recovering ICU patients. A validated
insulin glargine compartmental kinetics model and an
insulin-glucose pharmacodynamic model are used to per-
form simulation of protocols using glargine. Ten metabol-
ically stable patients who received insulin therapy under
SPRINT protocol during their stay in Christchurch Hos-
pital ICU were selected for in-silico assessments. Protocols
using daily injection of glargine reduced nursing effort pro-
vided blood glucose levels are largely maintained within a
desirable range. A protocol using glargine only for glucose
control did not show to be effective in the patients studied.
This may be an indication that a protocol using glargine
only is more suitable for the less acute wards. However,
an early, smooth transition from IV insulin to a com-
bination may help by reducing undesirable variations in
blood glucose levels. Finally, the use of glargine is shown to
supplement a patient’s basal insulin requirement without
the risk of hypoglycaemia.
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